Viral Therapeutics, Incorporated is a privately held, rapidly growing company with proprietary technologies. With an experienced management team and scientific staff, we are well-positioned to move our proprietary technologies and product development to the marketplace.
The VTI Advantage:
• Intellectual Property Portfolio
- Vagiprev exclusive worldwide rights
- Virus or exclusive worldwide rights
- Protein manufacturing technology (70 patents, Research Corporation Technologies)
- Herpes HSV recombinant protein license (25 patents, Chiron Corporation)
- Pharmacogenetics Portfolio:
- 11 Final Filings encompassing 34 diseases, 7 genes, and 336 SNP disease associations
- 96 Patent claims for end-stage renal disease treatment
- 10,000 Human Leukocyte samples comprising over 120 diseases
If you are interested in further investment information, please contact:
Viral Therapeutics, Incorporated
Attn: Lee Henderson, Ph.D.
Cornell Business and Technology Park
33 Thornwood Drive, Suite 104
Ithaca, NY 14850
607-266-0860
607-257-6356 (fax)